


Reltecimod TFA

Cat. No.:	HY-P1698B
Molecular Formula:	$C_{46}H_{72}N_{10}O_{15}S \cdot xC_2HF_3O_2$
Sequence:	Ala-Ser-Pro-Met-Leu-Val-Ala-Tyr-Asp-Ala
Sequence Shortening:	ASPMLVAYDA
Target:	Bacterial; CD28
Pathway:	Anti-infection; Immunology/Inflammation
Storage:	Sealed storage, away from moisture and light Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)



SOLVENT & SOLUBILITY

In Vitro	DMSO : 100 mg/mL (Need ultrasonic) H ₂ O : < 0.1 mg/mL (ultrasonic; adjust pH to 3 with HCl) (insoluble)
-----------------	--

BIOLOGICAL ACTIVITY

Description	Reltecimod (AB-103) TFA is a T-cell-specific surface glycoprotein CD28 (TP44) antagonist. Reltecimod TFA has beneficial effects against different bacterial infections, their exotoxins and endotoxins, and ionizing radiation. Reltecimod TFA modulates the inflammatory response by targeting and attenuating the critical CD28/B7-2 co-stimulatory pathway, without inhibiting it. Reltecimod TFA can be used to research necrotizing soft-tissue infections (NSTIs) ^[1] .
In Vivo	Reltecimod (1.25-5 mg/kg; i.v.) TFA increases the survival rate of mice infected with different bacteria ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Edgar, R., Tarrío, M.L., Maislin, G. et al. Treatment with One Dose of Reltecimod is Superior to Two Doses in Mouse Models of Lethal Infection. *Int J Pept Res Ther* 26, 1669–1683 (2020).

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA